Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Baxdrostat in Hepatic Impairment
NCT05961397Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of baxdrostat in hypertension (HTN) (2 arms), sponsored by AstraZeneca. Primary endpoints: Treatment Emergent Adverse Events up to 72 hours, Area Under the Curve up to 72 hours and 3 more. Started Aug 2021; status: completed.
02
Drugs
baxdrostat
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05961397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05961397.